Counterfeit drugs (WHO/EDM, 1999, 61 p.): (introductory text...)

Counterfeit drugs (WHO/EDM, 1999, 61 p.)

		*(introductory text...)*
		Executive Summary
		1. Introduction
		2. Overview of the problem
		3. Impact on public health
		4. Factors facilitating counterfeiting
		5. Developing national strategies
		6. Specific measures
		7. Assessment of the problem at the national level
		8. Inspection when pharmaceutical products are suspected to be counterfeit, spurious or substandard
		9. Test methods
		10. Developing training programmes: inspection and examination of counterfeit pharmaceuticals
		11. Conclusion
		References
		Selected further reading
		Acknowledgements
		Glossary

(introductory text...)

Guidelines for the development
of measures to combat
counterfeit drugs

Department of Essential Drugs and
Other Medicines
World Health Organization
Geneva, Switzerland

ORGANISATION MONDIALE DE LA SANTE

WHO/EDM/QSM/99.1
DISTR: GENERAL
ORIGINAL: ENGLISH

This document has been prepared under the auspices of the DMP-DAP Joint Project on Counterfeit Drugs which was administered by the World Health Organization Division of Drug Management and Policies (DMP) and the Action Programme on Essential Drugs (DAP) from 1995 to 1997. With effect from January 1999, the Department of Essential Drugs and Other Medicines Department (EDM) includes the former DAP and most components of DMP.

This document is not a formal publication of the World Health Organization (WHO) and all rights are reserved by the Organization. The document may, however, be freely reviewed, abstracted, reproduced, translated, in part or in whole, but not for sale nor for use in conjunction with commercial purposes.

The view expressed in documents by named authors are solely the responsibility of those authors.